A groundbreaking pilot program offering rapid genetic analysis for brain tumor patients is set to significantly improve both diagnosis and treatment, according to medical experts. The new DNA test, developed by teams at Nottingham University Hospitals NHS Trust and the University of Nottingham, can reduce standard diagnosis times from weeks to days. NHS England officials said the test will be trialed at specialist centers across the country. It works by quickly evaluating the genetic code from a tumor sample, enabling faster and more accurate identification of tumor types. Currently, identifying the precise type of brain tumor during surgery can take weeks, causing delays in treatment and clinical trial enrollment. With this new test, surgeons can confirm a diagnosis within two hours while an operation is ongoing. This allows for more timely and personalized treatment plans. NHS England emphasized that brain tumors are notoriously difficult to identify, with over 100 distinct forms ranging from slow-growing to highly aggressive cancers. Professor Frankie Swords, NHS England’s medical director, said the test could "completely transform" how brain tumors are diagnosed. "Results can reach patients in days rather than weeks," she said. "This is a huge leap forward for patients – a faster diagnosis means they can start the right treatment or access clinical trials sooner, while for some patients it could mean surgeons can make potentially life-changing decisions about their surgery while on the operating table." Stuart Smith, a consultant neurosurgeon and clinical associate professor at the University of Nottingham, described the test as "game-changing." He noted that having detailed tumor information during surgery allows for more informed decisions, such as how far to proceed to protect healthy brain tissue. Steve Palmer, a 55-year-old patient from Nottingham who was diagnosed with a grade 4 glioblastoma, said the rapid testing removed "weeks of anxiety." He emphasized how quickly receiving a definitive diagnosis allowed him to move swiftly into treatment and recovery. Health Secretary Yvette Cooper praised the development as an "incredible breakthrough," while Professor Dame Sue Hill, chief scientific officer for England, called it a "world-leading development" for NHS genomics. Researchers and charities have also welcomed the initiative, highlighting the potential of genomic testing to improve outcomes for brain tumor patients. Dr. Karen Noble of Brain Tumour Research noted that current testing times are often too long to inform care and trial access, especially for aggressive tumors. The pilot is seen as a promising step toward reducing delays and providing much-needed certainty for patients and their families.